Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$71.88 - $107.17
Previous CloseN/A
Volume5.49M
Average Volume (3M)6.60M
Market Cap
$151.04B
Enterprise Value$163.16B
Total Cash (Recent Filing)$725.00M
Total Debt (Recent Filing)$11.71B
Price to Earnings (P/E)74.8
Beta0.83
Next Earnings
Jul 23, 2025EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding1,479,446,300
10 Day Avg. Volume6,740,475
30 Day Avg. Volume6,601,627
Financial Highlights & Ratios
PEG Ratio7.85
Price to Book (P/B)6.84
Price to Sales (P/S)0.00
P/FCF Ratio52.97
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit13.84
Enterprise Value/Ebitda10.63
Forecast
1Y Price Target
$120.40Price Target Upside17.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Boston Scientific News
Bulls Say, Bears Say
Bulls Say
Growth DriversBSX expects to offset the impact of the ACURATE discontinuation with its other growth drivers including continued strong growth from FARAPULSE and WATCHMAN.
Market PositionBSX has seen its EP share increase to #2 in certain markets and is executing to become clear leader in the electrophysiology space.
Revenue OpportunitiesBSX expects to disrupt how mapping is done with the recent launch of Faraview and Farawave Nav, which can be an incremental $2k-$4k revenue opportunity per case.
Bears Say
Product DiscontinuationBoston Scientific announced the discontinuation of global Acurate neo2 and Acurate Prime TAVR valve sales, announcing that it would no longer be pursuing approval in the U.S. or other regions.
Regulatory ChallengesThe decision was driven by recent discussions with US and European regulators, and management felt that the increased clinical evidence and regulatory hurdles needed to maintain product approvals globally for ACURATE would not be worth the investment.
Ownership Overview
0.17% Insiders
29.63% Mutual Funds
18.64% Other Institutional Investors
29.16% Public Companies and Individual Investors
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $71.88 and its highest was $107.17 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $151.04B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Jul 23, 2025 which is in 44 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Apr 23, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.673 by $0.077.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.73.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,479,446,300 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.75 in its last earnings report, beating expectations of $0.673. Following the earnings report the stock price went up 4.072%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.40 (17.94% Upside)
$120.40 (17.94% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 78%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 892.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $418.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.11%
12-Months-Change
Fundamentals
Return on Equity
9.65%
Trailing 12-Months
Asset Growth
9.47%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation (BSX) is a leading global medical technology company that develops, manufactures, and markets a wide range of medical devices used in various interventional medical specialties. The company operates in three main sectors: Cardiovascular, Rhythm Management, and MedSurg. Its core products include stents, catheters, pacemakers, implantable cardioverter-defibrillators, and other devices used in interventional cardiology, electrophysiology, endoscopy, urology, and pelvic health.
BSX Company Deck
BSX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong revenue and EPS growth exceeding expectations, particularly in the cardiology and electrophysiology segments. However, challenges such as significant tariff impacts, slower growth in certain segments, and foreign exchange headwinds were noted, adding some concerns to the otherwise strong performance.Read More>BSX Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
BSX Stock 12 Month Forecast
Average Price Target
$120.40
▲(17.94%Upside)